Spyre Therapeutics, Inc. Reports Q2 2026 Financial Results

What Happened
Spyre Therapeutics, Inc. announced its financial results for the second quarter ended June 30, 2026 via a press release issued on August 4, 2026. The company furnished that press release as Exhibit 99.1 to its Form 8-K (Item 2.02: Results of Operations and Financial Condition). The report was signed by Scott Burrows, Chief Financial Officer.

Key Details

• Filing date: August 4, 2026 (Form 8-K submitted to the SEC).
• Reporting period: Quarter ended June 30, 2026.
• Disclosure type: Item 2.02 — press release reporting second‑quarter financial results (Exhibit 99.1).
• Form signature: /s/ Scott Burrows, Chief Financial Officer.

Why It Matters
An Item 2.02 8-K signals the company has released its quarterly operating and financial results; these results can affect share price and investor decisions. This filing itself furnishes the press release but does not include the detailed financial tables in the 8-K text — investors should review the Exhibit 99.1 press release for revenue, earnings (or losses), cash position, and any guidance or commentary provided by management. No other material events (e.g., executive changes, mergers, bankruptcies) were reported in this filing.